Bristol Myers Squibbb击败了Q3收入估算, 提升了2025年的指引, Bristol Myers Squibb beat Q3 earnings estimates, raised 2025 guidance, and sees strong institutional interest.

Bristol Myers Squibb报告10月30日的Q3收入比预期的要强, Bristol Myers Squibb reported stronger-than-expected Q3 earnings on October 30, posting $1.63 EPS, beating estimates by $0.11, and generating $12.22 billion in revenue, up 2.8% year-over-year. 该公司将其2025年全年EPS指导提高到6.40至6.60美元,分析师预测为6.74美元。 The company raised its 2025 full-year EPS guidance to $6.40–$6.60, with analysts projecting $6.74. 股票交易额为48.70美元,市场上限为99.14亿美元,红利收益率为5.1%。 The stock, trading at $48.70, has a market cap of $99.14 billion and a 5.1% dividend yield. 机构所有权仍然很高,占76.41%,几家公司的股份增加,而其他公司则减少股份。 Institutional ownership remains high at 76.41%, with several firms increasing stakes while others reduced holdings. 共识分析师评级是“坚持”,目标价格为55.45美元。 The consensus analyst rating is "Hold" with a target price of $55.45.